alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Exon 20 in-frame insertions'],"[{'ncitCode': 'C124993', 'drugName': 'Amivantamab'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['37870976', '32414908', '34339292']",[],"Amivantamab, an EGFR-MET specific antibody that targets EGFR activating mutations as well as MET mutations and amplifications, is FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. FDA approval was based on the results of the CHRYSALIS Phase I study of amivantamab in 81 patients with EGFR exon 20-mutant NSCLC who were previously treated with platinum agents in which the overall response rate was 40% (three patients with complete response; 95% CI=29 – 51) with a median duration of response of 11.1 months (95% CI=6.9 to not reached) and a median progression-free survival (PFS) of 8.3 months (95% CI=6.5 to 10.9) (PMID: 34339292). In the Phase III PAPILLON trial of amivantamab plus chemotherapy in 308 patients with EGFR exon 20-mutant NSCLC who have had disease progression during or after platinum-based chemotherapy, patients treated with amivantamab plus chemotherapy (n=153) demonstrated a median PFS of 11.4 months (95% CI=9.8 to 13.7) and an objective response rate (ORR) of 73% (95% CI=65 to 80) whereas the chemotherapy arm (n=155) demonstrated a median PFS of 6.7 months (95% CI=5.6 to 7.3) (HR=0.40 [95% CI=0.30 to 0.53], P<0.001) and an ORR of 47% (95% CI=39 to 56) (HR=1.50 [95% CI=1.32 to 1.68], P<0.001) (PMID: 37870976). Preclinical studies with Ba/F3 cells and patient-derived xenograft models harboring EGFR exon 20 insertion mutations demonstrate sensitivity to amivantamab as measured by inhibition of cellular proliferation and down-modulated EGFR-MET levels (PMID: 32414908)."
['Oncogenic Mutations'],"[{'ncitCode': 'C151967', 'drugName': 'Datopotamab Deruxtecan'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['39761483', '39250535']",[],"Datopotamab deruxtecan (Dato-DXd) is an intravenously infused, TROP2-directed antibody drug conjugate that is FDA-approved for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. FDA approval is based on the results of the Phase II TROPION-Lung05 (NCT04484142) and Phase III TROPION-Lung01 (NCT04656652) trials of Dato-DXd in patients with previously treated EGFR-mutated NSCLC.
In the Phase II TROPION-Lung05 (NCT04484142) trial of Dato-DXd in patients with NSCLC harboring actionable alterations progressing on or after targeted therapy and platinum-based chemotherapy, patients with EGFR-mutated NSCLC (n=78 [exon 19 deletion: 41 (29.9%); exon 20 T790M: 26 (19.0%); exon 21 L858R: 25 (18.2%); exon 18 G719: 5 (3.6%); exon 21 L861Q: 3 (2.2%); exon 20 insertion: 2 (1.5%)]) demonstrated an overall response rate (ORR) of 43.6% (95% CI=32.4-55.3), with a 5.1% (n=4) complete response (CR) rate, 38.5% (n=30) partial response (PR) rate and 34.6% (n=27) stable disease (SD) rate, a disease control rate (DCR) of 82.1% (95% CI=71.7-89.8), a median duration of response (DOR) of 7.0 months (95% CI=4.2-10.2) and a median progression-free survival (PFS) of 5.8 months (95% CI=5.4-8.3) (PMID: 39761483).
In the Phase III TROPION-Lung01 (NCT04656652) trial of Dato-DXd versus docetaxel in patients with pretreated NSCLC, patients treated with Dato-DXd (n=299 [EGFR mutations: 39 (13.0%)]) demonstrated an ORR of 26.4% (95% CI= 21.5-31.8), with a 1.3% (n=4) CR rate, 25.1% (n=75) PR rate and 49.8% (n=149) SD rate, a DCR of 77.3% (95% CI=72.1-81.9), a median DOR of 7.1 months (95% CI=5.6-10.9), a median PFS of 4.4 months (95% CI=4.2-5.6) and a median overall survival (OS) of 12.9 months (95% CI=11.0-13.9) (PMID: 39250535). Patients treated with docetaxel (n=305 [EGFR mutations: 45 (14.8%)]) demonstrated an ORR of 12.8% (95% CI=9.3-17.1), with a 12.8% (n=39) PR rate and 50.2% (n=153) SD rate, a DCR of 64.9% (95% CI=59.3-70.3), a median DOR of 5.6 months (95% CI=5.4-8.1), a median PFS of 3.7 months (95% CI=2.9-4.2) (HR=0.75 [95% CI=0.62-0.91]; p=.004) and a median OS of 11.8 months (95% CI=10.1-12.8) (HR=0.94 [95% CI=0.78-1.14]; p=0.530) (PMID: 39250535)."
['Exon 20 in-frame insertions'],"[{'ncitCode': 'C167205', 'drugName': 'Sunvozertinib'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],[],"[{'link': 'https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.8513', 'abstract': 'Yang et al. Abstract #8513, ASCO 2024.'}]","Sunvozertinib is an orally available EGFR tyrosine kinase inhibitor that is FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. EGFR exon 20 insertion mutations selected for treatment with sunovzertinib were detected by the Oncomine Dx Express Test. FDA approval was based on the results of the Phase I/II WU-KONG1B (NCT03974022) trial of sunvozertinib in patients with NSCLC with an EGFR exon 20 in-frame insertion with disease progression on or after platinum-based chemotherapy. 
In the Phase I/II WU-KONG1B (NCT03974022) trial, patients with pre-treated NSCLC harboring EGFR exon 20 insertion mutations (n=85) demonstrated an overall response rate of 46% (95% CI=35-57), with a 6% complete response rate and 40% partial response rate, and a median duration of response of 11.1 months (95% CI=8.2-NE) (Abstract: Yang et al. Abstract #8513, ASCO 2024. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.8513)."
['Exon 20 in-frame insertions'],"[{'ncitCode': 'C124993', 'drugName': 'Amivantamab'}, {'ncitCode': 'C15632', 'drugName': 'Chemotherapy'}]",[],LEVEL_1,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['37870976'],[],"Amivantamab is an intravenously infused, EGFR-MET bispecific monoclonal antibody that is FDA-approved for the treatment of adult patients in combination with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations as detected by an FDA-approved test. EGFR exon 20 insertion mutation status was identified through the Guardant Health Guardant360 CDx test. FDA approval was based on the results of the Phase III PAPILLON (NCT04538664) trial of amivantamab plus carboplatin and pemetrexed versus carboplatin and pemetrexed in 308 patients with previously untreated locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. In the Phase III PAPILLON (NCT04538664) trial, the amivantamab plus carboplatin and pemetrexed treated cohort (n=153) demonstrated a median progression-free survival (PFS) of 11.4 months (95% CI=9.8-13.7) and an overall response rate (ORR) of 67% (95% CI=59-75), with a 4% complete response (CR) rate and 63% partial response (PR) rate, compared to the carboplatin and pemetrexed treated cohort (n=155) that demonstrated a median PFS of 6.7 months (95% CI=5.6-7.3) (HR=0.40 [95% CI=0.30-0.53]; p<0.0001) and an ORR of 36% (95% CI=29-44), with a 1% CR rate and 36% PR rate (PMID: 37870976)."
['A763_Y764insFQEA'],"[{'ncitCode': 'C65530', 'drugName': 'Erlotinib'}]",[],LEVEL_2,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['23371856', '23969006', '24353160', '28089594']",[],"Erlotinib, a first-generation EGFR tyrosine kinase inhibitor (TKI), is FDA-approved for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations receiving first-line, maintenance, or second-or-greater line treatment after progression following at least one prior chemotherapy regimen. In vitro characterization of A763_Y764insFQEA demonstrated that it had an IC50 of < 0.05µM to erlotinib, which is more than ten-fold lower than the clinically achievable serum concentrations of this drug, and submicromolar concentrations of erlotinib inhibited phosphorylation of EGFR in A763_Y764insFQEA mutant Ba/F3 cells, leading to deactivation of the PI3K/AKT and MAPK/ERK pathways and subsequently inducing apoptosis (PMID: 24353160). In a study of 33 patients with NSCLC with exon 20 insertions, one patient harbored an A763_Y764insFQEA mutation and was treated with erlotinib in combination with chemotherapy and had a partial response (PMID: 23371856). In a case study of a single adult patient with NSCLC harboring an A763_Y764insFQEA mutation who was treated with erlotinib following disease progression after treatment with chemotherapy, the patient achieved a partial response at the two-month CT imaging assessment and at five months showed stable disease (PMID: 23969006). In a retrospective study of six patients harboring the EGFR exon 20 insertion A763_Y764insFQEA, two were treated with erlotinib, resulting in a partial response in one patient and progressive disease in the other, with progression-free survival rates of 14.5 and three months, respectively (PMID: 28089594)."
['Exon 20 in-frame insertions'],"[{'ncitCode': 'C98838', 'drugName': 'Poziotinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['35820397', '27188206', '29686424']",[],"Poziotinib is a second-generation, irreversible tyrosine kinase inhibitor (TKI) of EGFR, HER2 and HER4. There is promising clinical data that supports the use of poziotinib in patients with non-small cell lung cancers (NSCLC) harboring EGFR exon 20 insertions.
Prior to launching an investigator-initiated trial of poziotinib in EGFR exon 20 mutated advanced NSCLC, a single patient with metastatic NSCLC that exhibited a HER2 A771insAYVM mutation (a HER2 exon 20 insertion that behaves like an EGFR exon 20 insertion) was treated with poziotinib and had a pronounced clinical and radiological response (PMID: 29686424). In a Phase II (NCT01718847) study of poziotinib in 39 patients with NSCLC with activating EGFR mutations who developed acquired resistance to EGFR-TKIs, three of 39 (8%; 95% CI=2-21) and seventeen of 39 (44%; 95% CI=28-60) patients had partial responses and stable disease, respectively, and the median progression-free survival (PFS) and overall survival was 2.7 months (95% CI=1.8-3.7) and 15.0 months (95% CI=9.5-NE), respectively (PMID: 27188206). In a Phase II (NCT03066206) study of poziotinib in 50 patients with advanced NSCLC with point mutations or insertions in EGFR exon 20, overall response rates for patients overall, patients with near-loop mutations and patients with far-loop mutations were 32.0% (95% CI=20.7-45.8, n=16), 46% and 0%, respectively(PMID: 35820397). Additionally, the disease control rate was 84.0% (95% CI=71.5-92.0) and the median PFS and overall survival were 5.5 months (95% CI=5.4-10.4) and 19.2 months (95% CI=11.8-24.1) in these populations, respectively (PMID: 35820397). 
In vitro, poziotinib was shown to be approximately 40 times more potent than afatinib and 65 times more potent than dacomitinib at inhibiting growth in Ba/F3 cell lines bearing different EGFR exon 20 insertions (PMID: 29686424). In genetically engineered mouse models and xenograft models harboring an EGFR exon 20 insertion, poziotinib resulted in 80% tumor reduction in four weeks and 50% tumor reduction in ten days, whereas afatinib did not reduce tumor burden in either model (PMID: 29686424)."
['Exon 20 in-frame insertions'],"[{'ncitCode': 'C165567', 'drugName': 'Zipalertinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['37384848', '31467113']","[{'link': 'https://www.annalsofoncology.org/article/S0923-7534(24)02830-8/fulltext', 'abstract': 'Passaro et al. ESMO 2024.'}]","Zipalertinib is an orally available, irreversible EGFR tyrosine kinase inhibitor with broad activity against EGFR exon 20 insertions. There is promising clinical data that supports the use of zipalertinib in patients with non-small cell lung cancers (NSCLC) harboring EGFR exon 20 insertions.
In the Phase I/IIa REZILIENT1 (NCT04036682) trial of zipalertinib in 70 evaluable patients with advanced NSCLC harboring EGFR exon 20 insertion mutations, results reported that 25/70 patients (36%) had a partial response (PR) (seven unconfirmed, one pending confirmation), 34/70 patients (49%) had stable disease (SD) and 3/70 patients (4%) had progressive disease (PD) as best response (PMID: 37384848). In the subcohort results of the Phase IIb REZILIENT1 (NCT04036682) trial of zipalertinib in 45 patients with EGFR exon 20 mutant-NSCLC that progressed after prior amivantamab treatment, the overall response rate was 40%, with one patient (3%) demonstrating complete response, eleven patients (37%) demonstrating PR and fifteen patients (50%) demonstrating SD, the disease control rate was 90% and the median progression-free survival was 9.7 months (Abstract: Passaro et al. ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02830-8/fulltext).
In vivo xenograft data has demonstrated sensitivity of EGFR Exon 20 insertions to zipalertinib as measured by tumor shrinkage comparable to poziotinib, without the dose-limiting toxicity of poziotinib (PMID: 31467113)."
['A763_Y764insFQEA'],"[{'ncitCode': 'C66940', 'drugName': 'Afatinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['26515464'],[],"Afatinib, a second-generation, irreversible tyrosine kinase inhibitor of EGFR, HER2, and HER4, is NCCN-listed and FDA-approved for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations. Both the human lung adenocarcinoma cell line BID007, which harbors the A763_Y764insFQEA mutation, and murine Ba/F3 cells transduced with A763_Y764insFQEA were found to be sensitive to afatinib with IC50s of 8 nM and 3 nM, respectively (PMID: 26515464)."
